Protecting Product-Market Fit

TL;DR: Early traction is when it is easy for MedTech teams to stop watching the thing that produced it.

The first commercial wins change how the company operates. You have a few dozen live sites and a real pipeline, and the people on the team are no longer spending their week trying to figure out whether the thing works. The product, sales, clinical, and finance teams are all tracking against their KPIs. 

The question that often starts to get overlooked is whether the original PMF continues to hold.

That is the shift too many teams miss. Product-market fit in MedTech is not a box you check after the first paid sites come online. It is a living condition. Clinical value, workflow fit, economic proof, and the willingness of a multi-stakeholder buyer to keep saying yes can all drift while revenue is still moving in the right direction. By the time adoption starts to feel like a harder slog, the damage has usually been accumulating for months.

Why the discipline fades
Early on, the constraints do the work for you. Runway is short, investors want proof that a real problem exists for a defined set of users, and the founder is in the accounts hearing the friction before it shows up in a dashboard.

Once bookings appear, attention moves to the metrics the board can see every month: pipeline, close rate, headcount against plan. Fit gets treated as already solved. Teams assume that if they execute harder, with more reps, more features, and more pilots, the early resonance will persist on its own.

It rarely does. In a multi-stakeholder sale, the signal gets noisier as you add sites. A handful of engaged clinical champions gave you a clean read. A few dozen hospitals, with different specialties, IT environments, and Value Analysis Committee habits, will not. Fit becomes easier to ignore until expansion stalls, cycles lengthen, or margins compress.

Sean Ellis’s old test is still useful here, even if you never run the survey formally. When 40% or more of users would be “very disappointed” if the product disappeared, you have a strong signal. Below that, growth tends to be fragile. The point is not the number. The point is that fit can be measured, and it can weaken after you thought you had it.

What changes when nobody owns the whole view
PMF is not a departmental metric. Product can ship the roadmap and still dilute the original promise. Commercial can hit bookings by selling into a persona the workflow was never built for. Clinical can fill a journal queue that does not answer the economic questions the next committee will ask. Finance can watch unit economics after the damage is already in the cohort.

Ben Horowitz named a software version of this more than a decade ago: “The only thing that will wreck a company faster than the product CEO being highly engaged in the product is the product CEO disengaging from the product.” In MedTech it happens one layer out. The live question is not only whether the product stays coherent. It is whether the original clinical, workflow, and economic fit still holds once each team is optimizing its own number.

Ultimate accountability still belongs with the CEO. That does not mean the CEO runs every implementation. It means someone at the top is still looking across those local wins and asking whether the company is solving a painful enough problem for the people who have to live with it.
Customer success and implementation usually see the erosion first, because they are closest to whether a first site expands or quietly stalls. If those field signals have no path into an executive conversation, they die in a ticket queue.

Leading indicators of PMF erosion
It rarely arrives as a single bad quarter. You notice that time to value is stretching, or that it varies wildly from site to site. The first accounts still like you and are not pulling the next ones. New opportunities need a custom evidence pack every time. The founder is still on the late-stage calls because the story only holds when the person who discovered the problem tells it, and implementation still needs heroics from the original team.

None of that reads as a miss on a functional dashboard, because those dashboards measure activity. They were never built to tell you whether fit is intact.

This is also where the Adoption Gap comes back, even for companies that thought they had crossed it. Crossing it once, with a small set of engaged sites, is not the same as keeping it crossed as volume and complexity rise. Growth can hide a soft landing inside the first accounts for a long time.

What to keep watching
You do not need a new operating system. You need a short, recurring look at leading signals instead of waiting for revenue to explain itself.
Ask whether new sites are reaching useful value on a timeline the buyer will tolerate, and whether that timeline is stable as you add volume. Ask whether expansion inside existing accounts is getting easier or harder. Ask whether the core story is still true for the personas you are now selling to, or whether commercial has drifted into a neighboring use case because it was easier to close. Ask whether the evidence you are generating still matches what the next committee and the next payer will demand. Ask whether unit economics at the account level are improving as the process gets more repeatable, or whether each new site still requires the same white-glove cost.

When pressure mounts, the reflex is to sell harder. Sometimes that is the right call. Sometimes the pipeline is soft because the fit has slipped and more activity will only add expensive noise. The useful pause is to separate those two problems before you staff up.

A lightweight review is enough if it is real. A monthly cadence is appropriate once you have a repeatable commercial motion. Product, commercial, clinical, and whoever owns the post-sale experience should be in the same conversation, looking at the same leading indicators, with the CEO still accountable for the whole. Treat the health of fit as a visible executive metric next to pipeline and margin, not as a workshop you ran last year.

A short pressure test
If you have first commercial wins in the books, these questions usually tell you more than a revenue slide:

1. Who at the executive level is responsible for the health of product-market fit across the company, not just inside one function?
2. Can someone other than the founder explain why the last three wins looked the same, and why the last stall looked different?
3. Is time to value getting shorter and more consistent, or longer and more variable as you add sites?
4. Are first accounts expanding because the workflow earned it, or sitting still while the team hunts net-new logos?
5. When a new committee asks for proof, how much of the package already exists versus how much has to be built from scratch?
6. If you stopped founder-led selling next quarter, would the motion still produce the same quality of customer?

Honest answers here are usually enough to see whether you are protecting fit or assuming it.

The companies that keep growing without spending years repairing the foundation treat this as permanent work. They do not wait for churn or a painful board meeting to discover that the early resonance did not survive the org chart.

Does this strike a chord?
The free 7-Lever Self-Assessment is built for this window: first commercial wins on the board, and a real question about whether the underlying fit is still strong enough to scale. It gives you a readout of where the gaps sit and what to put first. You can get it free through the form on the homepage.

If you want to walk through the results or pressure-test the next 6–12 months, I’m happy to do a focused strategy conversation. Hit the Book a Call button at the top of the page.